nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—PSMA1—epithelium—gallbladder cancer	0.0334	0.085	CbGeAlD
Bortezomib—PSMD1—pancreas—gallbladder cancer	0.025	0.0635	CbGeAlD
Bortezomib—PSMD2—pancreas—gallbladder cancer	0.0221	0.0563	CbGeAlD
Bortezomib—PSMB8—pancreas—gallbladder cancer	0.022	0.0559	CbGeAlD
Bortezomib—PSMB5—pancreas—gallbladder cancer	0.0194	0.0494	CbGeAlD
Bortezomib—PSMA1—liver—gallbladder cancer	0.0189	0.0482	CbGeAlD
Bortezomib—PSMB1—pancreas—gallbladder cancer	0.017	0.0432	CbGeAlD
Bortezomib—PSMB2—pancreas—gallbladder cancer	0.0166	0.0421	CbGeAlD
Bortezomib—PSMD1—liver—gallbladder cancer	0.0159	0.0404	CbGeAlD
Bortezomib—CTSG—lymph node—gallbladder cancer	0.0151	0.0385	CbGeAlD
Bortezomib—PSMA1—lymph node—gallbladder cancer	0.0145	0.0369	CbGeAlD
Bortezomib—PSMD2—liver—gallbladder cancer	0.0141	0.0358	CbGeAlD
Bortezomib—PSMB8—liver—gallbladder cancer	0.014	0.0356	CbGeAlD
Bortezomib—PSMB5—liver—gallbladder cancer	0.0124	0.0314	CbGeAlD
Bortezomib—PSMD1—lymph node—gallbladder cancer	0.0122	0.031	CbGeAlD
Bortezomib—PSMB1—liver—gallbladder cancer	0.0108	0.0275	CbGeAlD
Bortezomib—PSMD2—lymph node—gallbladder cancer	0.0108	0.0275	CbGeAlD
Bortezomib—PSMB8—lymph node—gallbladder cancer	0.0107	0.0273	CbGeAlD
Bortezomib—PSMB2—liver—gallbladder cancer	0.0105	0.0268	CbGeAlD
Bortezomib—PSMB5—lymph node—gallbladder cancer	0.00948	0.0241	CbGeAlD
Bortezomib—SLC31A1—liver—gallbladder cancer	0.00914	0.0232	CbGeAlD
Bortezomib—PSMB1—lymph node—gallbladder cancer	0.00829	0.0211	CbGeAlD
Bortezomib—PSMB2—lymph node—gallbladder cancer	0.00809	0.0206	CbGeAlD
Bortezomib—SLC31A1—lymph node—gallbladder cancer	0.007	0.0178	CbGeAlD
Bortezomib—CYP1A1—epithelium—gallbladder cancer	0.00547	0.0139	CbGeAlD
Bortezomib—PTGS1—epithelium—gallbladder cancer	0.00481	0.0122	CbGeAlD
Bortezomib—CYP2C19—liver—gallbladder cancer	0.00385	0.00979	CbGeAlD
Bortezomib—CYP2C8—liver—gallbladder cancer	0.00336	0.00854	CbGeAlD
Bortezomib—CYP1A2—liver—gallbladder cancer	0.00315	0.008	CbGeAlD
Bortezomib—CYP1A1—liver—gallbladder cancer	0.0031	0.00789	CbGeAlD
Bortezomib—CYP2C9—liver—gallbladder cancer	0.00299	0.00759	CbGeAlD
Bortezomib—CYP1A1—lymph node—gallbladder cancer	0.00238	0.00605	CbGeAlD
Bortezomib—CYP3A4—liver—gallbladder cancer	0.00228	0.00579	CbGeAlD
Bortezomib—CYP2D6—liver—gallbladder cancer	0.00224	0.0057	CbGeAlD
Bortezomib—PTGS1—lymph node—gallbladder cancer	0.00209	0.00531	CbGeAlD
Bortezomib—PSMB2—B Cell Activation—NRAS—gallbladder cancer	0.00101	0.00166	CbGpPWpGaD
Bortezomib—PSMB1—B Cell Activation—NRAS—gallbladder cancer	0.00101	0.00166	CbGpPWpGaD
Bortezomib—PSMB8—B Cell Activation—NRAS—gallbladder cancer	0.000995	0.00164	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—ERBB4—gallbladder cancer	0.000986	0.00163	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—ERBB4—gallbladder cancer	0.000986	0.00163	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—ERBB4—gallbladder cancer	0.000986	0.00163	CbGpPWpGaD
Bortezomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—KRAS—gallbladder cancer	0.000983	0.00162	CbGpPWpGaD
Bortezomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—KRAS—gallbladder cancer	0.000983	0.00162	CbGpPWpGaD
Bortezomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—KRAS—gallbladder cancer	0.000983	0.00162	CbGpPWpGaD
Bortezomib—PSMA1—B Cell Activation—HRAS—gallbladder cancer	0.000974	0.00161	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—ERBB4—gallbladder cancer	0.000972	0.0016	CbGpPWpGaD
Bortezomib—PSMD1—B Cell Activation—HRAS—gallbladder cancer	0.000969	0.0016	CbGpPWpGaD
Bortezomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—KRAS—gallbladder cancer	0.000969	0.0016	CbGpPWpGaD
Bortezomib—PSMD2—B Cell Activation—HRAS—gallbladder cancer	0.000965	0.00159	CbGpPWpGaD
Bortezomib—PSMB5—Apoptosis—TP53—gallbladder cancer	0.000927	0.00153	CbGpPWpGaD
Bortezomib—PSMB1—Apoptosis—TP53—gallbladder cancer	0.000927	0.00153	CbGpPWpGaD
Bortezomib—PSMB2—Apoptosis—TP53—gallbladder cancer	0.000927	0.00153	CbGpPWpGaD
Bortezomib—PSMB2—B Cell Activation—EGFR—gallbladder cancer	0.000919	0.00152	CbGpPWpGaD
Bortezomib—PSMB5—B Cell Activation—EGFR—gallbladder cancer	0.000919	0.00152	CbGpPWpGaD
Bortezomib—PSMB1—B Cell Activation—EGFR—gallbladder cancer	0.000919	0.00152	CbGpPWpGaD
Bortezomib—PSMB8—Apoptosis—TP53—gallbladder cancer	0.000914	0.00151	CbGpPWpGaD
Bortezomib—PSMB8—B Cell Activation—EGFR—gallbladder cancer	0.000906	0.00149	CbGpPWpGaD
Bortezomib—PSMB2—B Cell Activation—KRAS—gallbladder cancer	0.000868	0.00143	CbGpPWpGaD
Bortezomib—PSMB1—B Cell Activation—KRAS—gallbladder cancer	0.000868	0.00143	CbGpPWpGaD
Bortezomib—PSMB5—B Cell Activation—KRAS—gallbladder cancer	0.000868	0.00143	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—gallbladder cancer	0.000863	0.00142	CbGpPWpGaD
Bortezomib—PSMB8—B Cell Activation—KRAS—gallbladder cancer	0.000856	0.00141	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—ERBB3—gallbladder cancer	0.000853	0.00141	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—ERBB3—gallbladder cancer	0.000853	0.00141	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—ERBB3—gallbladder cancer	0.000853	0.00141	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—ERBB3—gallbladder cancer	0.000841	0.00139	CbGpPWpGaD
Bortezomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—gallbladder cancer	0.000835	0.00138	CbGpPWpGaD
Bortezomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—gallbladder cancer	0.000835	0.00138	CbGpPWpGaD
Bortezomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—HRAS—gallbladder cancer	0.000835	0.00138	CbGpPWpGaD
Bortezomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—HRAS—gallbladder cancer	0.000824	0.00136	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—ERBB4—gallbladder cancer	0.000789	0.0013	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—ERBB4—gallbladder cancer	0.000786	0.00129	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—ERBB4—gallbladder cancer	0.000782	0.00129	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—gallbladder cancer	0.000752	0.00124	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—NRAS—gallbladder cancer	0.000745	0.00123	CbGpPWpGaD
Bortezomib—PSMB5—B Cell Activation—HRAS—gallbladder cancer	0.000738	0.00122	CbGpPWpGaD
Bortezomib—PSMB2—B Cell Activation—HRAS—gallbladder cancer	0.000738	0.00122	CbGpPWpGaD
Bortezomib—PSMB1—B Cell Activation—HRAS—gallbladder cancer	0.000738	0.00122	CbGpPWpGaD
Bortezomib—PSMA1—Disease—ERBB4—gallbladder cancer	0.000729	0.0012	CbGpPWpGaD
Bortezomib—PSMB8—B Cell Activation—HRAS—gallbladder cancer	0.000728	0.0012	CbGpPWpGaD
Bortezomib—PSMD1—Disease—ERBB4—gallbladder cancer	0.000725	0.0012	CbGpPWpGaD
Bortezomib—PSMD2—Disease—ERBB4—gallbladder cancer	0.000722	0.00119	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—ERBB2—gallbladder cancer	0.000705	0.00116	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—ERBB2—gallbladder cancer	0.000702	0.00116	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—ERBB2—gallbladder cancer	0.000699	0.00115	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—gallbladder cancer	0.000685	0.00113	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—gallbladder cancer	0.000685	0.00113	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—ERBB3—gallbladder cancer	0.000682	0.00112	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—ERBB3—gallbladder cancer	0.000679	0.00112	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—ERBB3—gallbladder cancer	0.000676	0.00111	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—gallbladder cancer	0.000648	0.00107	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—KRAS—gallbladder cancer	0.000641	0.00106	CbGpPWpGaD
Bortezomib—PSMA1—Disease—ERBB3—gallbladder cancer	0.00063	0.00104	CbGpPWpGaD
Bortezomib—PSMD1—Disease—ERBB3—gallbladder cancer	0.000627	0.00103	CbGpPWpGaD
Bortezomib—PSMD2—Disease—ERBB3—gallbladder cancer	0.000624	0.00103	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—ERBB4—gallbladder cancer	0.000598	0.000986	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—ERBB4—gallbladder cancer	0.000598	0.000986	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—ERBB4—gallbladder cancer	0.000598	0.000986	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—ERBB4—gallbladder cancer	0.00059	0.000972	CbGpPWpGaD
Bortezomib—PSMB2—Disease—ERBB4—gallbladder cancer	0.000552	0.00091	CbGpPWpGaD
Bortezomib—PSMB5—Disease—ERBB4—gallbladder cancer	0.000552	0.00091	CbGpPWpGaD
Bortezomib—PSMB1—Disease—ERBB4—gallbladder cancer	0.000552	0.00091	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—gallbladder cancer	0.00055	0.000907	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—HRAS—gallbladder cancer	0.000545	0.000898	CbGpPWpGaD
Bortezomib—PSMB8—Disease—ERBB4—gallbladder cancer	0.000544	0.000898	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—NRAS—gallbladder cancer	0.000537	0.000885	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—ERBB2—gallbladder cancer	0.000535	0.000881	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—ERBB2—gallbladder cancer	0.000535	0.000881	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—ERBB2—gallbladder cancer	0.000535	0.000881	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—NRAS—gallbladder cancer	0.000534	0.00088	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—NRAS—gallbladder cancer	0.000532	0.000876	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—ERBB2—gallbladder cancer	0.000527	0.000869	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—ERBB3—gallbladder cancer	0.000517	0.000853	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—ERBB3—gallbladder cancer	0.000517	0.000853	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—ERBB3—gallbladder cancer	0.000517	0.000853	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—ERBB4—gallbladder cancer	0.00051	0.000841	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—ERBB3—gallbladder cancer	0.00051	0.00084	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—ERBB4—gallbladder cancer	0.000508	0.000837	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—ERBB4—gallbladder cancer	0.000505	0.000833	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—EGFR—gallbladder cancer	0.000489	0.000806	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—EGFR—gallbladder cancer	0.000487	0.000802	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—EGFR—gallbladder cancer	0.000484	0.000798	CbGpPWpGaD
Bortezomib—PSMB5—Disease—ERBB3—gallbladder cancer	0.000477	0.000787	CbGpPWpGaD
Bortezomib—PSMB2—Disease—ERBB3—gallbladder cancer	0.000477	0.000787	CbGpPWpGaD
Bortezomib—PSMB1—Disease—ERBB3—gallbladder cancer	0.000477	0.000787	CbGpPWpGaD
Bortezomib—PSMB8—Disease—ERBB3—gallbladder cancer	0.000471	0.000776	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—KRAS—gallbladder cancer	0.000462	0.000761	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—KRAS—gallbladder cancer	0.00046	0.000758	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—KRAS—gallbladder cancer	0.000458	0.000754	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—TP53—gallbladder cancer	0.000448	0.000739	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—TP53—gallbladder cancer	0.000446	0.000735	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—TP53—gallbladder cancer	0.000444	0.000732	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—ERBB3—gallbladder cancer	0.000441	0.000727	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—BCL2—gallbladder cancer	0.00044	0.000726	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—ERBB3—gallbladder cancer	0.000439	0.000724	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—BCL2—gallbladder cancer	0.000438	0.000723	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—ERBB3—gallbladder cancer	0.000437	0.00072	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—BCL2—gallbladder cancer	0.000436	0.000719	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—ERBB2—gallbladder cancer	0.000428	0.000705	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—ERBB2—gallbladder cancer	0.000426	0.000702	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—ERBB2—gallbladder cancer	0.000424	0.000699	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—NRAS—gallbladder cancer	0.000407	0.00067	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—NRAS—gallbladder cancer	0.000407	0.00067	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—NRAS—gallbladder cancer	0.000407	0.00067	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—NRAS—gallbladder cancer	0.000401	0.000661	CbGpPWpGaD
Bortezomib—PSMA1—Disease—ERBB2—gallbladder cancer	0.000395	0.000651	CbGpPWpGaD
Bortezomib—PSMD1—Disease—ERBB2—gallbladder cancer	0.000393	0.000648	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—HRAS—gallbladder cancer	0.000393	0.000647	CbGpPWpGaD
Bortezomib—PSMD2—Disease—ERBB2—gallbladder cancer	0.000391	0.000645	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—HRAS—gallbladder cancer	0.000391	0.000644	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—HRAS—gallbladder cancer	0.000389	0.000641	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ERBB4—gallbladder cancer	0.000387	0.000638	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ERBB4—gallbladder cancer	0.000387	0.000638	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ERBB4—gallbladder cancer	0.000387	0.000638	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ERBB4—gallbladder cancer	0.000381	0.000629	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—EGFR—gallbladder cancer	0.000371	0.000611	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—EGFR—gallbladder cancer	0.000371	0.000611	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—EGFR—gallbladder cancer	0.000371	0.000611	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—EGFR—gallbladder cancer	0.000365	0.000602	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—KRAS—gallbladder cancer	0.00035	0.000577	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—KRAS—gallbladder cancer	0.00035	0.000577	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—KRAS—gallbladder cancer	0.00035	0.000577	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—KRAS—gallbladder cancer	0.000345	0.000569	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—gallbladder cancer	0.00034	0.00056	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—gallbladder cancer	0.00034	0.00056	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—gallbladder cancer	0.00034	0.00056	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—gallbladder cancer	0.000335	0.000552	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ERBB3—gallbladder cancer	0.000334	0.000551	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ERBB3—gallbladder cancer	0.000334	0.000551	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ERBB3—gallbladder cancer	0.000334	0.000551	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—BCL2—gallbladder cancer	0.000334	0.00055	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—BCL2—gallbladder cancer	0.000334	0.00055	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—BCL2—gallbladder cancer	0.000334	0.00055	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ERBB3—gallbladder cancer	0.00033	0.000543	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—BCL2—gallbladder cancer	0.000329	0.000542	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—NRAS—gallbladder cancer	0.000326	0.000537	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—ERBB2—gallbladder cancer	0.000324	0.000535	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—ERBB2—gallbladder cancer	0.000324	0.000535	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—ERBB2—gallbladder cancer	0.000324	0.000535	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—NRAS—gallbladder cancer	0.000324	0.000534	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—NRAS—gallbladder cancer	0.000322	0.000532	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—ERBB2—gallbladder cancer	0.00032	0.000527	CbGpPWpGaD
Bortezomib—PSMA1—Disease—NRAS—gallbladder cancer	0.000301	0.000495	CbGpPWpGaD
Bortezomib—PSMB2—Disease—ERBB2—gallbladder cancer	0.000299	0.000494	CbGpPWpGaD
Bortezomib—PSMB1—Disease—ERBB2—gallbladder cancer	0.000299	0.000494	CbGpPWpGaD
Bortezomib—PSMB5—Disease—ERBB2—gallbladder cancer	0.000299	0.000494	CbGpPWpGaD
Bortezomib—PSMD1—Disease—NRAS—gallbladder cancer	0.000299	0.000493	CbGpPWpGaD
Bortezomib—PSMD2—Disease—NRAS—gallbladder cancer	0.000298	0.000491	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HRAS—gallbladder cancer	0.000298	0.000491	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HRAS—gallbladder cancer	0.000298	0.000491	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HRAS—gallbladder cancer	0.000298	0.000491	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—EGFR—gallbladder cancer	0.000297	0.000489	CbGpPWpGaD
Bortezomib—PSMB8—Disease—ERBB2—gallbladder cancer	0.000295	0.000487	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—EGFR—gallbladder cancer	0.000295	0.000487	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—EGFR—gallbladder cancer	0.000294	0.000484	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—HRAS—gallbladder cancer	0.000293	0.000484	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—KRAS—gallbladder cancer	0.00028	0.000462	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—KRAS—gallbladder cancer	0.000279	0.00046	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—KRAS—gallbladder cancer	0.000277	0.000457	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—ERBB2—gallbladder cancer	0.000277	0.000456	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—ERBB2—gallbladder cancer	0.000275	0.000454	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—ERBB2—gallbladder cancer	0.000274	0.000452	CbGpPWpGaD
Bortezomib—PSMA1—Disease—EGFR—gallbladder cancer	0.000274	0.000451	CbGpPWpGaD
Bortezomib—PSMD1—Disease—EGFR—gallbladder cancer	0.000272	0.000449	CbGpPWpGaD
Bortezomib—PSMD2—Disease—EGFR—gallbladder cancer	0.000271	0.000447	CbGpPWpGaD
Bortezomib—PSMA1—Disease—KRAS—gallbladder cancer	0.000259	0.000426	CbGpPWpGaD
Bortezomib—PSMD1—Disease—KRAS—gallbladder cancer	0.000257	0.000424	CbGpPWpGaD
Bortezomib—PSMD2—Disease—KRAS—gallbladder cancer	0.000256	0.000422	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—NRAS—gallbladder cancer	0.000247	0.000407	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—NRAS—gallbladder cancer	0.000247	0.000407	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—NRAS—gallbladder cancer	0.000247	0.000407	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—NRAS—gallbladder cancer	0.000243	0.000401	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—HRAS—gallbladder cancer	0.000238	0.000393	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HRAS—gallbladder cancer	0.000237	0.000391	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—HRAS—gallbladder cancer	0.000236	0.000389	CbGpPWpGaD
Bortezomib—PSMB5—Disease—NRAS—gallbladder cancer	0.000228	0.000375	CbGpPWpGaD
Bortezomib—PSMB2—Disease—NRAS—gallbladder cancer	0.000228	0.000375	CbGpPWpGaD
Bortezomib—PSMB1—Disease—NRAS—gallbladder cancer	0.000228	0.000375	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—EGFR—gallbladder cancer	0.000225	0.000371	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—EGFR—gallbladder cancer	0.000225	0.000371	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—EGFR—gallbladder cancer	0.000225	0.000371	CbGpPWpGaD
Bortezomib—PSMB8—Disease—NRAS—gallbladder cancer	0.000225	0.00037	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—EGFR—gallbladder cancer	0.000222	0.000365	CbGpPWpGaD
Bortezomib—PSMA1—Disease—HRAS—gallbladder cancer	0.00022	0.000362	CbGpPWpGaD
Bortezomib—PSMD1—Disease—HRAS—gallbladder cancer	0.000219	0.000361	CbGpPWpGaD
Bortezomib—PSMD2—Disease—HRAS—gallbladder cancer	0.000218	0.000359	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KRAS—gallbladder cancer	0.000212	0.00035	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KRAS—gallbladder cancer	0.000212	0.00035	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KRAS—gallbladder cancer	0.000212	0.00035	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NRAS—gallbladder cancer	0.00021	0.000347	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ERBB2—gallbladder cancer	0.00021	0.000346	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ERBB2—gallbladder cancer	0.00021	0.000346	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ERBB2—gallbladder cancer	0.00021	0.000346	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NRAS—gallbladder cancer	0.000209	0.000345	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KRAS—gallbladder cancer	0.000209	0.000345	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NRAS—gallbladder cancer	0.000208	0.000344	CbGpPWpGaD
Bortezomib—PSMB2—Disease—EGFR—gallbladder cancer	0.000208	0.000342	CbGpPWpGaD
Bortezomib—PSMB1—Disease—EGFR—gallbladder cancer	0.000208	0.000342	CbGpPWpGaD
Bortezomib—PSMB5—Disease—EGFR—gallbladder cancer	0.000208	0.000342	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ERBB2—gallbladder cancer	0.000207	0.000341	CbGpPWpGaD
Bortezomib—PSMB8—Disease—EGFR—gallbladder cancer	0.000205	0.000337	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KRAS—gallbladder cancer	0.000196	0.000323	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KRAS—gallbladder cancer	0.000196	0.000323	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KRAS—gallbladder cancer	0.000196	0.000323	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KRAS—gallbladder cancer	0.000193	0.000319	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EGFR—gallbladder cancer	0.000192	0.000316	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EGFR—gallbladder cancer	0.000191	0.000315	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EGFR—gallbladder cancer	0.00019	0.000313	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KRAS—gallbladder cancer	0.000181	0.000299	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—gallbladder cancer	0.00018	0.000298	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—gallbladder cancer	0.00018	0.000298	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—gallbladder cancer	0.00018	0.000298	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KRAS—gallbladder cancer	0.00018	0.000297	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KRAS—gallbladder cancer	0.000179	0.000296	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—gallbladder cancer	0.000178	0.000293	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—gallbladder cancer	0.000167	0.000275	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—gallbladder cancer	0.000167	0.000275	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—gallbladder cancer	0.000167	0.000275	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—gallbladder cancer	0.000164	0.000271	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—gallbladder cancer	0.000161	0.000265	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—gallbladder cancer	0.00016	0.000264	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NRAS—gallbladder cancer	0.000159	0.000263	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NRAS—gallbladder cancer	0.000159	0.000263	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NRAS—gallbladder cancer	0.000159	0.000263	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—gallbladder cancer	0.000159	0.000263	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NRAS—gallbladder cancer	0.000157	0.000259	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—gallbladder cancer	0.000154	0.000254	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—gallbladder cancer	0.000153	0.000253	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—gallbladder cancer	0.000153	0.000251	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—gallbladder cancer	0.000145	0.00024	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—gallbladder cancer	0.000145	0.00024	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—gallbladder cancer	0.000145	0.00024	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—gallbladder cancer	0.000143	0.000236	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—gallbladder cancer	0.000137	0.000226	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—gallbladder cancer	0.000137	0.000226	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—gallbladder cancer	0.000137	0.000226	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—gallbladder cancer	0.000135	0.000223	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—gallbladder cancer	0.000122	0.000201	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—gallbladder cancer	0.000122	0.000201	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—gallbladder cancer	0.000122	0.000201	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—gallbladder cancer	0.00012	0.000198	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—gallbladder cancer	0.000117	0.000192	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—gallbladder cancer	0.000117	0.000192	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—gallbladder cancer	0.000117	0.000192	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—gallbladder cancer	0.000115	0.00019	CbGpPWpGaD
